Beam Therapeutics Profit Margin 2019-2021 | BEAM

Current and historical gross margin, operating margin and net profit margin for Beam Therapeutics (BEAM) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Beam Therapeutics net profit margin as of September 30, 2021 is -51395.01%.
Beam Therapeutics Annual Profit Margins
Beam Therapeutics Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.234B $0.000B
Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.281B 7.66
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.681B 21.48
Biohaven Pharmaceutical Holding (BHVN) United States $7.357B 0.00
Arcus Biosciences (RCUS) United States $3.170B 0.00
Emergent Biosolutions (EBS) United States $2.265B 8.14
Myovant Sciences (MYOV) United Kingdom $1.741B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.500B 0.00
Zymeworks (ZYME) Canada $0.902B 0.00
Ambrx Biopharma (AMAM) United States $0.391B 0.00
SQZ Biotechnologies (SQZ) United States $0.337B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.95